These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30222423)

  • 1. Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients.
    Shah A
    Ther Innov Regul Sci; 2015 Mar; 49(2):256-261. PubMed ID: 30222423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program.
    Conrad R; Taylor K; Raggio M; Harrington A; Stark G; Kish A; Bertha A
    Ther Innov Regul Sci; 2017 Jul; 51(4):509-515. PubMed ID: 30227048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug development in serious diseases: the new "breakthrough therapy" designation.
    Woodcock J
    Clin Pharmacol Ther; 2014 May; 95(5):483-5. PubMed ID: 24747238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing standards for breakthrough therapy designation in oncology.
    Horning SJ; Haber DA; Selig WK; Ivy SP; Roberts SA; Allen JD; Sigal EV; Sawyers CL
    Clin Cancer Res; 2013 Aug; 19(16):4297-304. PubMed ID: 23719260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA reform signed into law. Food and Drug Administration.
    James JS
    AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
    Poirier AF; Murphy WR
    Clin Pharmacol Ther; 2016 Dec; 100(6):603-605. PubMed ID: 27513678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 21st century cures act: Opportunities and challenges.
    Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2015 Dec; 98(6):575-7. PubMed ID: 26264909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough therapy-designated oncology drugs: are they rightfully criticized?
    Mulder J; Pasmooij AMG; Stoyanova-Beninska VV; Schellens JHM
    Drug Discov Today; 2020 Sep; 25(9):1580-1584. PubMed ID: 32562841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.
    Herink MC; Irwin AN; Zumach GM
    Pharmacotherapy; 2018 Sep; 38(9):967-980. PubMed ID: 30043413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA's Expedited Programs and Their Impact on the Availability of New Therapies.
    Damle N; Shah S; Nagraj P; Tabrizi P; Rodriguez GE; Bhambri R
    Ther Innov Regul Sci; 2017 Jan; 51(1):24-28. PubMed ID: 30235999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importing a change in diet: the proposed food safety law of 2010 and the possible impact on importers and international trade.
    May SG
    Food Drug Law J; 2010; 65(1):1-35, i. PubMed ID: 24475533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. House vote on Hyde changes dynamic of Congressional abortion debate.
    Wash Memo Alan Guttmacher Inst; 1993 Jul; (12):1-2. PubMed ID: 12286695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.